BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.
Phase 1
Completed
- Conditions
- Pharmacology, Clinical
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT02394093
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2
Completed
- Conditions
- Diffuse, Large B-Cell, Lymphoma
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 67
- Registration Number
- NCT02391116
Roniciclib Mass Balance Study
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT02390154
- Locations
- ππΊ
PRA Magyarorszag Kft. Fazis I-es Klin.Farmakol. Vizsgalohely, Budapest, Hungary
BAY1238097, First in Man
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- Drug: BAY 1238097
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8
- Registration Number
- NCT02369029
Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
Phase 1
Terminated
- Conditions
- Medical Oncology
- Interventions
- Drug: BAY1187982
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT02368951
Phase III Copanlisib in Rituximab-refractory iNHL
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25
- Registration Number
- NCT02369016
Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT02367027
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Phase 3
Active, not recruiting
- Conditions
- Lymphoma,Non-Hodgkin
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 458
- Registration Number
- NCT02367040
- Locations
- πΊπΈ
MSK Bergen, New Jersey, New Jersey, United States
πΊπΈMSK Monmoth, New Jersey, New Jersey, United States
πΊπΈMSK Westchester, Harrison, New York, United States
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 75
- Registration Number
- NCT02366949
Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: BAY 1841788(ODM-201)
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 9
- Registration Number
- NCT02363855
Β© Copyright 2025. All Rights Reserved by MedPath